Movement Alert｜Akeso Rises 3.44% in Regular Trading, Buyback Support and Broker Buy Rating Trigger Rebound Near 52-Week Low

Market Focus06-23 09:39

On June 23, Akeso rose 3.44% in regular trading, trading at HK$86.1/share, with turnover of HK$135 million. On the news front, the stock approached its 52-week low of HK$82.85 in the previous session, triggering a technical oversold rebound supported by corporate buyback measures and a maintained bullish broker rating.

The company's board previously approved a share repurchase plan of up to HK$200 million, along with management share purchases of up to HK$50 million combined. Xingye Securities issued a research report maintaining its Buy rating, citing the ivonescimab HARMONi-6 overall survival data as a milestone achievement, projecting the drug could generate over US$15 billion in revenue by 2033. The stock had fallen more than 30% from its post-ASCO peak following sustained profit-taking after the positive OS results were announced on June 1. The convergence of industrial capital support, technical oversold conditions, and fundamental reaffirmation jointly triggered the current rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170628820?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 09:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170628820","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Akeso Rises 3.44% in Regular Trading, Buyback Support and Broker Buy Rating Trigger Rebound Near 52-Week Low","media":"Market Focus","content":"<p><p>On June 23, Akeso rose 3.44% in regular trading, trading at HK$86.1/share, with turnover of HK$135 million. On the news front, the stock approached its 52-week low of HK$82.85 in the previous session, triggering a technical oversold rebound supported by corporate buyback measures and a maintained bullish broker rating.</p><p>The company's board previously approved a share repurchase plan of up to HK$200 million, along with management share purchases of up to HK$50 million combined. Xingye Securities issued a research report maintaining its Buy rating, citing the ivonescimab HARMONi-6 overall survival data as a milestone achievement, projecting the drug could generate over US$15 billion in revenue by 2033. The stock had fallen more than 30% from its post-ASCO peak following sustained profit-taking after the positive OS results were announced on June 1. The convergence of industrial capital support, technical oversold conditions, and fundamental reaffirmation jointly triggered the current rebound.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Rises 3.44% in Regular Trading, Buyback Support and Broker Buy Rating Trigger Rebound Near 52-Week Low</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Rises 3.44% in Regular Trading, Buyback Support and Broker Buy Rating Trigger Rebound Near 52-Week Low\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-23 09:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 23, Akeso rose 3.44% in regular trading, trading at HK$86.1/share, with turnover of HK$135 million. On the news front, the stock approached its 52-week low of HK$82.85 in the previous session, triggering a technical oversold rebound supported by corporate buyback measures and a maintained bullish broker rating.</p><p>The company's board previously approved a share repurchase plan of up to HK$200 million, along with management share purchases of up to HK$50 million combined. Xingye Securities issued a research report maintaining its Buy rating, citing the ivonescimab HARMONi-6 overall survival data as a milestone achievement, projecting the drug could generate over US$15 billion in revenue by 2033. The stock had fallen more than 30% from its post-ASCO peak following sustained profit-taking after the positive OS results were announced on June 1. The convergence of industrial capital support, technical oversold conditions, and fundamental reaffirmation jointly triggered the current rebound.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1170628820","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170628820","pubTimestamp":1782178770,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 23, Akeso rose 3.44% in regular trading, trading at HK$86.1/share, with turnover of HK$135 million. On the news front, the stock approached its 52-week low of HK$82.85 in the previous...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"走势提示|康方生物常规交易涨3.44%回购支持及券商买入评级触发反弹接近52周低点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On June 23, Akeso rose 3.44% in regular trading, trading at HK$86.1/share, with turnover of HK$135 million. On the news front, the stock approached its 52-week low of HK$82.85 in the previous session, triggering a technical oversold rebound supported by corporate buyback measures and a maintained bullish broker rating.The company's board previously approved a share repurchase plan of up to HK$200 million, along with management share purchases of up to HK$50 million combined. Xingye Securities issued a research report maintaining its Buy rating, citing the ivonescimab HARMONi-6 overall survival data as a milestone achievement, projecting the drug could generate over US$15 billion in revenue by 2033. The stock had fallen more than 30% from its post-ASCO peak following sustained profit-taking after the positive OS results were announced on June 1. The convergence of industrial capital support, technical oversold conditions, and fundamental reaffirmation jointly triggered the current rebound.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170628820","isCrawlerRequest":true}